Universal reference book for medicines
Product name: RINVIR (RINVIR)

Active substance: ritonavir

Type: Antiviral drug active against HIV

Manufacturer: IRVIN 2 (Russia) manufactured by LOK-BETA PHARMACEUTICALS (I) (India)
Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..

PHARMACHOLOGIC EFFECT
An antiviral agent.
Has a selective affinity for HIV asparyl protease and therefore has a weak inhibitory effect on the corresponding human protease.
In vitro studies have shown that ritonavir has a pronounced inhibitory effect on the replication of both laboratory and clinical strains of HIV.

Ritonavir is almost completely metabolized in the liver.

INDICATIONS
Treatment of infections caused by HIV.

DOSING MODE
When ingested by adults - 600 mg 2 times / day.
To reduce the side effect on the first day, you can apply 300 mg 2 times / day, followed by a gradual increase in the dose of 100 mg until the recommended dose.
In children it is recommended to use in combination with antiviral analogues of nucleosides.
The recommended dose is 400 mg / m 2 2 times / day. To reduce the side effect, you can start taking a dose of 250 mg / m 2 , with a further increase every 2-3 days by 50 mg / m 2 per reception until you reach a dose of 400 mg / m 2 2 times / day . Determination of the dose for children is recommended to be carried out according to a special nomogram table.
SIDE EFFECT
On the part of the digestive system: often - anorexia, nausea, vomiting, diarrhea, dry mouth, ulcerative lesions of the oral mucosa, eructations, flatulence, impaired functional liver tests;
an increase in liver and digestive enzymes.
From the side of the central nervous system and the peripheral nervous system: often - fear, insomnia, paresthesia around the mouth and on the periphery, dizziness, drowsiness.

From the respiratory system: laryngitis, cough, pharyngitis are possible.

On the part of the hemopoietic system: a decrease in hemoglobin, a decrease in hematocrit, a decrease in the number of erythrocytes, a decrease in the number of leukocytes, a decrease in the number of neutrophils, an increase in the number of eosinophils.

On the part of metabolism: increased uric acid, hyperlipidemia, weight loss, decreased potassium content, increased triglycerides.

Dermatological reactions: skin rash, itching, increased sweating.

Other: widening of peripheral vessels, myalgia.

CONTRAINDICATIONS
Hypersensitivity to ritonavir.

Simultaneous use with amiodarone, astemizole, itraconazole, ketoconazole, bepridilum, cisapride, bupropion, clozapine, dihydroergotamine, ergotamine, enkainide, flecainide, meperidine, nimozide, piroxicam, propafenone, propoxyphene, quinidine, rifabutin, terfenadine, sodium clorazepate, flurazepam, diazepam, estazolam, midazolam, triazolam, zolpidem, alprazolam.

PREGNANCY AND LACTATION
With caution and in cases of extreme need to apply during pregnancy and lactation.

APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
Use with caution in patients with liver disease.

During the treatment period, it is necessary to regularly monitor the liver function in patients with a previous increase in the level of liver enzymes and in hepatitis, as well as long-term treatment and in elderly patients.

APPLICATION FOR CHILDREN
The application is possible according to the dosing regimen.

APPLICATION IN ELDERLY PATIENTS
During the treatment period, it is necessary to regularly monitor the liver function in elderly patients.

SPECIAL INSTRUCTIONS
Use with caution in patients with liver disease.

During the treatment period, it is necessary to regularly monitor the liver function in patients with a previous increase in the level of liver enzymes and in hepatitis, as well as long-term treatment and in elderly patients.

In patients with hemophilia A and B types, in some cases, the probability of developing bleeding (the appearance of cutaneous and joint hematomas) increases.

DRUG INTERACTION
Rifampin, rifabutin, and also smoking reduce the effect of ritonavir.

With simultaneous use with ritonavir, a reduction in the doses of the following drugs is required (due to a decrease in the intensity of their metabolism): clarithromycin in patients with renal insufficiency, desipramine, saquinavir.

When used simultaneously with ritonavir, doses of hormonal contraceptives for oral administration, theophylline, should be increased.

Ritonavir increases the average values ​​of AID sildenafil 11 times, clarithromycin and trimethoprim by 77% and 20%, respectively;
The AUC of rifabutin and its metabolite increases 4 and 35 times, respectively.
Ritonavir decreases the average values ​​of AUC zidovudine (26%), theophylline (45%), ethinyl estradiol (41%), sulfamethoxazole (20%);
these drugs do not have a significant effect on the pharmacokinetics of ritonavir.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y

Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!